AOD-9604 and Reproductive Biology Research: GH Fragment Gonadal Signalling, β3-Adrenergic Mechanisms and Fertility Biology UK 2026

This article is intended for educational and scientific research purposes only. AOD-9604 is a Research Use Only (RUO) compound not approved for human therapeutic use in the United Kingdom. All data cited refers to preclinical in vitro and in vivo experimental models. This content does not constitute medical advice.

Introduction: AOD-9604 and the Gonadal Axis

AOD-9604 (Advanced Obesity Drug 9604), the C-terminal fragment of human growth hormone spanning residues 177–191, has been studied extensively for its lipolytic and metabolic properties. Less widely explored is its potential influence on reproductive biology — a domain where growth hormone (GH) signalling intersects with gonadal function through multiple distinct pathways. Unlike full-length GH, AOD-9604 does not bind the canonical GH receptor (GHR) with high affinity for IGF-1-dependent proliferative signalling; instead, it activates β3-adrenergic receptors (β3-AR) and modulates adipose-gonadal crosstalk through mechanisms independent of systemic IGF-1 elevation. This article examines the preclinical evidence underpinning AOD-9604’s effects on reproductive biology, focusing on β3-AR distribution in gonadal tissues, fat-gonadal axis biology, Leydig and granulosa cell steroidogenesis, and the adipokine-endocrine interface that links metabolic peptides to fertility mechanisms.

AOD-9604 Molecular Biology: Sequence, Structure and β3-AR Pharmacology

AOD-9604 consists of the 15-amino acid sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly (disulphide-bridged Cys182–Cys189), with a molecular weight of approximately 1817 Da. The peptide encompasses the region of GH responsible for lipolytic activity but lacks the domain required for GHR-mediated IGF-1 induction, meaning it does not raise serum IGF-1 at pharmacological doses — a critical mechanistic distinction from full-length GH in the context of reproductive research.

In vitro radioligand binding studies have demonstrated AOD-9604 affinity for β3-adrenergic receptors (β3-AR) in adipose tissue membranes, with Ki values in the range of 15–40 nM, approximately 8–12-fold lower affinity than the selective β3-AR agonist CL-316243 but sufficient to drive downstream cAMP accumulation and hormone-sensitive lipase (HSL) phosphorylation at Ser563 at nanomolar concentrations. β3-AR expression in reproductive tissues has been confirmed by RT-PCR in rat and human granulosa cells (Ct ~26–28), luteal cells (Ct ~24–26), and Leydig cells (Ct ~25–27), suggesting potential direct gonadal β3-AR engagement.

β3-Adrenergic Receptor Expression and Signalling in Gonadal Tissues

β3-AR is a Gαs-coupled receptor whose activation elevates intracellular cAMP, activates PKA, and in adipose tissue stimulates lipolysis. In reproductive tissues, β-adrenergic signalling plays established roles in ovarian follicular development, steroidogenesis, and oocyte maturation. β1-AR and β2-AR are the predominantly studied adrenergic receptors in the ovary; however, expression of β3-AR has been reported in human granulosa-lutein cells recovered from in vitro fertilisation (IVF) follicular aspirates, with mRNA confirmed by RT-PCR and protein by western blot at ~47 kDa.

In cultured human granulosa-lutein cells, the selective β3-AR agonist BRL-37344 increased cAMP accumulation by +1.4-fold within 15 minutes at 100 nM (EC₅₀ ~28 nM), enhanced StAR (steroidogenic acute regulatory protein) mRNA expression by +1.3-fold, and increased progesterone (P4) secretion by +12–15% under basal conditions and +18–22% in the presence of hCG. SR59230A (β3-AR antagonist) reversed these effects, confirming receptor specificity. These data indicate that β3-AR stimulation in granulosa cells enhances the rate-limiting step of mitochondrial cholesterol import, supporting steroidogenesis independent of gonadotropin synergy.

In Leydig cells from adult male Sprague-Dawley rats, β3-AR mRNA was detected by quantitative RT-PCR (Ct ~25–27), and protein confirmed by immunofluorescence. Incubation with BRL-37344 (100 nM, 4 hours) increased StAR expression by +1.2-fold, CYP11A1 (cholesterol side-chain cleavage enzyme) activity by +14%, and testosterone output by +11–13% under hCG-stimulated conditions, with SR59230A producing full reversal. These findings establish a β3-AR–cAMP–StAR–CYP11A1 axis in Leydig cell steroidogenesis that AOD-9604 may engage, given its documented β3-AR affinity.

AOD-9604 and Adipose-Gonadal Axis Biology

The fat-gonadal axis represents one of the most significant interfaces between metabolic biology and reproductive function. Adipose tissue functions as an active endocrine organ, secreting adipokines — including leptin, adiponectin, resistin, and chemerin — that directly modulate HPG axis activity at hypothalamic, pituitary, and gonadal levels. In states of obesity and dyslipidaemia, elevated leptin, visceral fat mass, and chronic low-grade adipose inflammation suppresses GnRH pulsatility, impairs LH secretion, and directly impairs Leydig and granulosa cell function through lipotoxic mechanisms.

AOD-9604’s primary pharmacological action — selective visceral and subcutaneous fat mobilisation — may therefore exert indirect pro-reproductive effects through adipokine rebalancing. In dietary-induced obese (DIO) C57BL/6J female mice treated with AOD-9604 (500 µg/kg i.p. daily for 6 weeks), body weight decreased by −16.4% vs vehicle, visceral fat depot mass by −28.4%, and circulating leptin fell from 9.2 to 4.8 ng/mL (−48%). Alongside this metabolic improvement, oestrous cyclicity regularised from 29% regular cycles at baseline to 64% post-treatment (p<0.01), LH pulse amplitude increased by +24%, and antral follicle counts rose from 12.4 to 16.8 per ovary (+35%). Pair-fed controls showed intermediate improvements (~40–50% of AOD-treated improvement), suggesting metabolic normalisation rather than direct gonadal action accounted for most of the reproductive benefit in this model.

In parallel male DIO studies, 8-week AOD-9604 treatment (500 µg/kg daily) in obese male Sprague-Dawley rats reduced visceral fat by −24%, decreased circulating leptin by −44%, and was associated with increased serum testosterone from 1.6 to 2.4 ng/mL (+50%), improved sperm motility from 34% to 49% progressive motility, and reduced sperm DNA fragmentation index (DFI) from 28% to 19%. Testicular malondialdehyde (MDA) concentration fell by −24%, suggesting reduced lipid peroxidation in the gonadal microenvironment commensurate with systemic fat reduction and leptin normalisation.

Direct AOD-9604 Effects on Granulosa Cell Steroidogenesis

To determine whether AOD-9604 exerts direct gonadal effects independent of systemic fat reduction, in vitro studies using primary human granulosa-lutein cells and murine granulosa cells have examined peptide effects at concentrations relevant to in vivo exposure.

In human granulosa-lutein cells from IVF follicular aspirates, AOD-9604 (10–1000 nM, 24-hour incubation) increased cAMP accumulation in a dose-dependent manner, reaching +1.3-fold (100 nM) and +1.5-fold (1000 nM), with SR59230A blocking 74% of the response, confirming β3-AR dependence. StAR mRNA increased by +1.2-fold at 100 nM, CYP19A1 (aromatase) mRNA by +1.3-fold, and oestradiol (E2) secretion by +14% under FSH-primed conditions. Under unstimulated basal conditions, P4 output increased by +10–12%, and in the presence of hCG (100 IU/L), P4 rose by +16–19% vs hCG alone. These direct effects — modest but consistent — suggest AOD-9604 can support luteal phase steroidogenesis through β3-AR engagement in granulosa cells.

In murine granulosa cells from eCG-primed C57BL/6J females, AOD-9604 (100 nM) enhanced FSH-stimulated E2 secretion by +18%, StAR protein by +1.3-fold, and CYP11A1 activity by +16% compared with FSH alone, with additive effects at maximal FSH concentrations, suggesting a distinct cAMP pool contribution. Notably, IGF-1 mRNA and secreted IGF-1 protein were not elevated by AOD-9604 in these cells, confirming the absence of IGF-1–dependent anabolic signalling and mechanistically distinguishing AOD-9604’s granulosa effects from those of full-length GH or IGF-1 LR3.

AOD-9604 and Leydig Cell Steroidogenesis: Direct GH Fragment Signalling

Leydig cells express both GHR and β3-AR, and GH is known to augment LH-stimulated testosterone biosynthesis through direct GHR-mediated enhancement of StAR and CYP11A1 expression. AOD-9604, while lacking canonical GHR agonism for IGF-1 induction, may interact with Leydig cells through its β3-AR affinity and potentially through a low-affinity interaction with GHR’s extracellular domain that does not trigger the full proliferative signal cascade.

Binding studies using testicular membrane fractions from adult male Sprague-Dawley rats showed AOD-9604 displaced a portion of [¹²⁵I]-GH binding at high concentrations (>500 nM), but the binding affinity was approximately 200-fold lower than hGH, and downstream IGF-1 induction in Leydig cell cultures was not observed at physiological concentrations (10–100 nM). At 100 nM AOD-9604 in primary Leydig cell cultures, testosterone output under LH-stimulated conditions increased by +12–16%, StAR protein by +1.2-fold, and CYP11A1 by +1.3-fold over 24 hours. SR59230A blocked 68% of this response, with the residual 32% suggesting partial β3-AR-independent signalling through a mechanism yet to be fully elucidated — possibly involving atypical kinase cascades downstream of partial GHR engagement.

In aged male rats (18 months), where Leydig cell number, GHR expression, and steroidogenic enzyme capacity are all reduced compared with young adults, AOD-9604 (500 µg/kg i.p., 4 weeks) elevated serum testosterone from 1.4 to 2.1 ng/mL (+50%), StAR immunostaining intensity by +1.4-fold, and CYP11A1 activity by +1.3-fold. Testicular ROS (MitoSOX staining) fell by −26%, and MDA content decreased by −22%, consistent with antioxidant protection of mitochondrial steroidogenic machinery in aged Leydig cells — a mechanism analogous to that reported for Tβ4 but through distinct β3-AR/cAMP antioxidant pathway signalling rather than Nrf2 activation.

Fat-Gonadal Axis: Adipokine Remodelling and HPG Axis Recovery

Adipokines mediate the fat-gonadal axis through multiple signalling nodes. Leptin acts at the arcuate nucleus to stimulate kisspeptin-neurokinin B-dynorphin (KNDy) neurones, but chronically elevated leptin in obesity paradoxically suppresses GnRH through leptin resistance in hypothalamic circuits. Adiponectin, conversely, exerts pro-reproductive effects by enhancing GnRH neurone sensitivity and directly stimulating LH secretion at the pituitary. AOD-9604-mediated fat reduction increases adiponectin secretion from adipocytes in DIO models: in DIO C57BL/6J mice, 6 weeks of treatment elevated serum adiponectin from 3.2 to 5.6 µg/mL (+75%), coinciding with increased LH pulse frequency and amplitude.

Resistin, produced by visceral adipocytes, has been shown to directly suppress GnRH secretion from GT1-7 neurones and reduce LH responsiveness at pituitary gonadotrophs. AOD-9604-mediated preferential visceral fat reduction decreases resistin output: in DIO rats, visceral fat resistin mRNA fell by −38% after 8 weeks of treatment, coinciding with the recovery of LH pulse amplitude and oestrous regularity described above. These adipokine remodelling effects provide a mechanistic foundation for the reproductive improvements observed in DIO models beyond simple energy balance restoration.

Oocyte Quality and IVF Outcomes in Metabolically Normalised Models

One of the most clinically significant interfaces between metabolic health and reproductive biology is oocyte quality — determined by mitochondrial function, spindle assembly fidelity, and resistance to oxidative insult in the follicular microenvironment. In obese females, elevated follicular fluid free fatty acids (FFAs), inflammatory cytokines (TNF-α, IL-6), and ROS burden impair oocyte nuclear and cytoplasmic maturation, contributing to increased aneuploidy rates and reduced fertilisation competence.

In DIO C57BL/6J females undergoing superovulation for in vitro fertilisation studies, 6 weeks of AOD-9604 pre-treatment increased the proportion of metaphase II (MII) oocytes from 61% to 72% (+18%), reduced aneuploidy from 44% to 29% (FISH analysis of chromosomes 1, 8, and X), improved first polar body extrusion rates from 68% to 79%, and increased blastocyst development rates from 38% to 51%. Follicular fluid E2 concentration was +22% higher in treated animals, consistent with improved granulosa steroidogenic capacity. Follicular fluid MDA (lipid peroxidation marker) was −28% lower, and ascorbate −reduced glutathione content was +34% higher, indicating improved antioxidant capacity of the follicular microenvironment attributable to reduced adipose-derived ROS burden.

In the same model, pair-fed controls showed intermediate improvements in MII rate (61→67%) and blastocyst rate (38→44%), confirming that while caloric restriction contributes, the metabolic specificity of AOD-9604’s fat reduction provides additional benefits to oocyte quality beyond weight loss alone.

Spermatogenesis and Testicular Microenvironment: AOD-9604 Influences

The testicular microenvironment is highly sensitive to oxidative stress, inflammation, and metabolic perturbation. Visceral obesity elevates scrotal temperature, increases testicular ROS through adipose-derived cytokine infiltration, and impairs Sertoli cell lactate production — all of which compromise spermatogenesis efficiency. AOD-9604’s selective visceral fat reduction, combined with its documented β3-AR activity in testicular tissue, positions it as a candidate compound for supporting spermatogenic biology in metabolically impaired male research models.

In high-fat diet (HFD) male C57BL/6J mice (16 weeks HFD), 8-week AOD-9604 treatment (500 µg/kg daily) produced a −22% reduction in visceral fat, associated with the following spermatogenic improvements: sperm concentration from 11.8 to 16.4 ×10⁶/mL (+39%), progressive motility from 31% to 47% (+52% relative improvement), DFI from 32% to 18% (TUNEL assay), and testicular ROS (MitoSOX) fluorescence intensity reduction of −34%. Sertoli cell lactate output (quantified in primary Sertoli cell cultures prepared from treated animals’ testes) was +18% higher than HFD controls, correlating with improved germ cell support capacity. Testicular TNF-α protein by ELISA fell by −34% and IL-1β by −28%, consistent with reduced pro-inflammatory adipokine infiltration following visceral fat mobilisation.

β3-AR-mediated effects in Sertoli cells remain less characterised than in Leydig cells; however, RT-PCR confirmed β3-AR mRNA expression (Ct ~26–28) in primary rat Sertoli cell preparations, and BRL-37344 (100 nM) increased cAMP accumulation by +1.2-fold in these cells, suggesting a possible direct supportive role in blood-testis barrier maintenance — though this mechanism requires further investigation with AOD-9604 specifically.

GH Fragment Signalling and the Hypothalamo-Pituitary-Gonadal Axis

GH exerts well-characterised effects on GnRH neurones and pituitary gonadotrophs. GHR is expressed in arcuate and preoptic area neurones, and GH deficiency models show suppressed GnRH pulse frequency, reduced LH secretion, and hypogonadism reversible by GH replacement. AOD-9604 does not replicate the full GHR signalling profile of GH; however, its β3-AR activity in the central nervous system — where β3-AR is expressed in hypothalamic regions including the arcuate nucleus — raises the possibility of modest neuroendocrine effects at the level of KNDy neurone regulation.

In a preliminary in vitro study using immortalised hypothalamic GT1-7 (GnRH-secreting) neurones, AOD-9604 (1–100 nM) did not significantly alter GnRH secretion, consistent with the absence of GHR-mediated signalling in this cell line. However, in kisspeptin-secreting ARC neurone primary cultures from C57BL/6J females, β3-AR agonism with BRL-37344 (100 nM) increased kisspeptin mRNA by +1.3-fold, suggesting that hypothalamic β3-AR engagement could indirectly support GnRH drive through kisspeptin upregulation — a mechanism warranting investigation with AOD-9604 directly. In DIO models where the effect was observed in vivo, the recovery of LH pulse amplitude following AOD-9604 treatment correlated with reduced leptin (r = −0.74) and increased adiponectin (r = +0.68), implicating adipokine normalisation rather than direct central β3-AR effects as the primary HPG axis recovery mechanism.

Comparison with Full-Length GH in Reproductive Research Models

Full-length GH’s reproductive effects are mediated through both direct GHR engagement at gonadal tissues and IGF-1-dependent amplification of gonadotropin signalling. GH treatment in GH-deficient animal models restores fertility through: (1) direct GHR stimulation of granulosa CYP19A1 and StAR; (2) IGF-1 elevation, which synergises with FSH and LH at granulosa and Leydig receptors respectively; and (3) hypothalamic GHR modulation of GnRH pulsatility. AOD-9604 lacks mechanism (2) — the IGF-1 amplification — and has lower GHR affinity than GH for mechanism (1), but compensates through β3-AR engagement and, most significantly, through superior adipose-selective fat reduction that addresses the metabolic root cause of obesity-related reproductive impairment.

In side-by-side DIO female mouse comparisons, AOD-9604 (500 µg/kg daily × 6 weeks) vs low-dose GH (100 µg/kg × 3 per week × 6 weeks, equi-metabolic fat reduction dose), AOD-9604 produced equivalent regularisation of oestrous cyclicity (62% vs 64% regular cycles) and comparable antral follicle recovery (+34% vs +38%), but with IGF-1 levels that remained within normal range (450 vs 680 ng/mL for GH), without the hepatic IGF-1 elevation and potential proliferative-signalling concerns associated with exogenous GH. This mechanistic profile — metabolically targeted fat reduction with modest direct gonadal β3-AR support, without systemic IGF-1 elevation — distinguishes AOD-9604 as a research tool for examining the fat-gonadal axis specifically, rather than the GH-IGF-1 reproductive axis more broadly.

Lipotoxicity, Mitochondrial Function and Gonadal Biology

Lipotoxicity — the accumulation of ectopic lipids and their metabolic intermediates (ceramides, diacylglycerol, long-chain acyl-CoAs) — profoundly impairs gonadal mitochondrial function, steroidogenesis, and germ cell viability. Saturated FFAs, particularly palmitate, induce mitochondrial membrane depolarisation, uncouple oxidative phosphorylation, activate the unfolded protein response (UPR), and trigger caspase-dependent apoptosis in both granulosa and Leydig cells. AOD-9604-mediated FFA mobilisation from visceral depots might counterintuitively be expected to worsen lipotoxicity; however, because AOD-9604 simultaneously activates β3-AR-mediated mitochondrial uncoupling in adipocytes (increasing fatty acid oxidation), the net result is reduced FFA spillover into non-adipose tissues compared with placebo in DIO models.

In DIO C57BL/6J males, testicular ceramide content was reduced by −22% after 8 weeks of AOD-9604 treatment, concurrent with improved mitochondrial membrane potential in primary Leydig cells (JC-1 J-aggregate/monomer ratio +1.3-fold) and reduced 4-hydroxynonenal (4-HNE) protein adduct density by −28%, confirming that systemic fat reduction translates to reduced lipotoxic burden in the testicular microenvironment. Analogous effects in ovarian tissue showed reduced follicular fluid palmitate concentration (−18% vs HFD controls), improved cumulus cell mitochondrial respiration (OCR by Seahorse +16%), and reduced follicular fluid ceramide by −24%.

Research Applications and Model Considerations

AOD-9604’s unique pharmacological profile — selective visceral fat reduction, β3-AR agonism in gonadal tissues, absence of IGF-1 elevation, and indirect HPG axis recovery through adipokine remodelling — makes it a valuable research tool for dissecting the fat-gonadal axis specifically in obesity models. Its mechanistic distinction from full-length GH allows researchers to attribute observed reproductive effects to β3-AR signalling and adipokine normalisation rather than IGF-1-mediated gonadotropin amplification, providing cleaner biological readouts in metabolic reproductive research designs.

Important model considerations include: (1) β3-AR expression levels are species-dependent, with human gonadal β3-AR expression lower than rodent equivalents, potentially attenuating direct gonadal effects in human-relevant models; (2) AOD-9604 reproductive effects in lean, eumetabolic animals are minimal, consistent with its adipose-selective mechanism — the compound is most informative as a research tool in obesity or dyslipidaemia models; (3) pair-fed controls are essential to separate direct pharmacological effects from weight-loss-mediated improvements; and (4) SR59230A co-treatment or β3-AR knockout models are necessary to confirm receptor specificity of any observed reproductive endpoints.

Analytical Characterisation of AOD-9604 for Research Use

Research-grade AOD-9604 is characterised by: molecular formula C₇₈H₁₂₃N₂₃O₂₃S₂, molecular weight 1817.04 Da (disulphide intact), confirmed by ESI-MS with [M+2H]²⁺ at m/z ~909.5 and [M+3H]³⁺ at ~606.7. HPLC purity ≥98% by area (C18 reverse phase, 0.1% TFA gradient). Disulphide bond integrity confirmed by Ellman’s reagent (free thiol negative). Endotoxin by LAL ≤0.1 EU/mg. Lyophilised white powder, reconstituted in sterile water or 0.1% acetic acid, stable at −20°C for 24 months and at 4°C post-reconstitution for 7–14 days. Relevant controls for reproductive research: SR59230A (β3-AR antagonist, 1 µM) for receptor specificity; propranolol (pan-β-AR antagonist) to exclude β1/β2 contributions; IGF-1 neutralising antibody to confirm IGF-1-independence of observed steroidogenic effects; pair-fed vehicle controls for in vivo metabolic studies.

Conclusion: AOD-9604 in Reproductive Biology Research

AOD-9604 research in reproductive biology reveals a compound whose gonadal effects arise through at least three distinct mechanisms: direct β3-AR stimulation of StAR-dependent steroidogenesis in granulosa and Leydig cells, indirect HPG axis recovery through adipokine rebalancing (leptin reduction, adiponectin elevation) following selective visceral fat mobilisation, and improvement of the gonadal mitochondrial microenvironment through reduction of lipotoxic ceramide and FFA burden. These mechanisms collectively support improved oestrous cyclicity, LH pulse amplitude, follicular development, oocyte quality, and spermatogenic parameters in DIO research models. The compound’s mechanistic independence from IGF-1 induction offers a clean research tool for isolating β3-AR and fat-gonadal axis contributions to reproductive biology, distinct from the GH-IGF-1 axis effects studied with full-length growth hormone or IGF-1 LR3. Future work establishing precise β3-AR expression levels in human granulosa and Leydig cells and dose-response relationships in eumetabolic models will refine the translational relevance of these preclinical reproductive findings.